Integrated Filing — IndAS



General information about company

Scrip Code 532305
NSE Symbol INDSWFTLAB
MSEI Symbol NOTLISTED
ISIN INE915B01019
Name of company IND-SWIFT LABORATORIES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 29-10-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 15-10-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment PHARMACEUTICALS
Start date and time of board meeting 29-10-2026   12:00:00
End date and time of board meeting 29-10-2026   14:45:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. Yes
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 13-02-2025
Indicate Company website link for updated RPT policy of the Company https://www.indswiftlabs.com/wp-content/uploads/2025/05/Related_Party_Policy_01022025.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 2
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
NA



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 23,489.04 42,097.28
Other income 759.87 1,522.69
Total income 24,248.91 43,619.97
2 Expenses
(a) Cost of materials consumed 9,286.19 17,458.83
(b) Purchases of stock-in-trade 1,605.40 2,932.19
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (287.26) (2,265.49)
(d) Employee benefit expense 3,736.21 7,631.55
(e) Finance costs 133.31 203.83
(f) Depreciation, depletion and amortisation expense 777.09 1,535.39
(f) Other Expenses
1 Other expenses 4,915.76 8,775.09
Total other expenses 4,915.76 8,775.09
Total expenses 20,166.70 36,271.39
3 Total profit before exceptional items and tax 4,082.21 7,348.58
4 Exceptional items (57.97) (81.55)
5 Total profit before tax 4,024.24 7,267.03
6 Tax expense
7 Current tax 921.41 1,719.78
8 Deferred tax 0.00 0.00
9 Total tax expenses 921.41 1,719.78
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 3,102.83 5,547.25
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 3,102.83 5,547.25
17 Other comprehensive income net of taxes 0.00 0.00
18 Total Comprehensive Income for the period 3,102.83 5,547.25
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 8,696.16 8,696.16
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 3.57 6.38
Diluted earnings (loss) per share from continuing operations 3.56 6.36
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 3.57 6.38
Diluted earnings (loss) per share from continuing and discontinued operations 3.56 6.36
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes: - 1. During the quarter ended 30th September, 2026, the company has achieved an EBITDA of Rs. 42.33 Crores and earned a Standalone Net Profit of Rs. 31.03 Crores as compared to the EBITDA of Rs. 8.55 Crores and Standalone Net Profit of Rs. 8.76 Crores during the corresponding quarter of previous financial year. 2. The above Un-Audited Standalone and Consolidated Financial Results have been prepared considering the requirements of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended. These results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 29th October, 2026. The above results have been subjected to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified. 3. The Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30.09.2026 have been prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015. 4. The figures for the quarter ended March 31, 2026 were the balancing figures between audited figures in respect of full financial year and the year-to-date figures upto the third quarter of the previous financial year. 5. Exceptional items for the quarter ended 30th September, 2026 is Rs. 57.97 Lakhs whereas for 30th June, 2026 comprise of Rs. 23.58 Lakhs and for the financial year ended 31st March, 2026 of Rs. 1100.64 Lakhs, towards balances written back/written off (net) on account of amounts no longer payable/receivable. 6. The Company has invested the available surplus funds in various investment avenues which is regularly being monitored by the Investment Committee duly constituted by the Board of Directors of the Company. 7. The Consolidated financial results include the financial results of the parent company, Ind-Swift Laboratories Limited and the financial results of the following subsidiaries/Joint Venture: a) Ind-Swift Laboratories Inc., USA (Subsidiary) b) Fortune (India) Constructions Limited (Subsidiary) c) Indis Healthcare LLP (Joint Venture) d) MJM Remedies Private Limited (Subsidiary) e) ISLL Middle East LLC-FZ (Subsidiary) f) Ind Swift India Limited Kenya (Subsidiary) g) Capital Strikers LLP (Joint Venture) Ind-Swift Laboratories Limited and its subsidiaries are collectively referred to as ‘the Group’. 8. No adjustment has been made in respect of Deferred Taxes as per Ind-AS 12, as the same would be provided at year end. 9. During the quarter under review the Company has not issued any Non-Convertible Debt Securities. 10. The previous period figures have been re-grouped and re-classified wherever necessary. 11. The Company is exclusively in the Pharmaceutical Business segment. Place: Chandigarh For Ind-Swift Laboratories Limited Date: 29th October, 2026 Navrattan Munjal Chairman



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 27,353.96
Capital work-in-progress 3,978.64
Investment property 220.17
Goodwill 0.00
Other intangible assets 3,489.48
Intangible assets under development 203.43
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 32,391.97
Trade receivables, non-current
Loans, non-current 7,354.40
Other non-current financial assets
1 Other 216.69
Total of other non-current financial assets 216.69
Total non-current financial assets 39,963.06
Deferred tax assets (net) 5,033.70
Other non-current assets
1 Other non-current assets 3,355.77
Total of other non-current assets 3,355.77
Total non-current assets 83,598.21
2 Current assets
Inventories 16,835.17
Current financial asset
Current investments 4,502.84
Trade receivables, current 23,478.52
Cash and cash equivalents 32,281.43
Bank balance other than cash and cash equivalents 0.00
Loans, current 0.00
Other current financial assets
Total of other current financial assets 3,369.89
Total current financial assets 63,632.68
Current tax assets (net)
Other current assets
1 Other current assets 11,362.45
Total of other current assets 11,362.45
Total current assets 91,830.30
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 1,75,428.51
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 8,696.16
Other equity 1,37,362.49
Total equity attributable to owners of parent 1,46,058.65
Non controlling interest
Total equity 1,46,058.65
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 1,514.45
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities
1 Other non-current financial liabilities 576.56
Total of other non-current financial liabilities 576.56
Total non-current financial liabilities 2,091.01
Provisions, non-current 1,356.19
Deferred tax liabilities (net)
Deferred government grants, Non-current
Other non-current liabilities
1 Other non-current liabilities 19.51
Total of other non-current liabilities 19.51
Total non-current liabilities 3,466.71
Current liabilities
Current financial liabilities
Borrowings, current 435.44
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 80.89
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 13,288.85
Total Trade payable 13,369.74
Other current financial liabilities
1 Other current financial liabilities 159.67
Total of other current financial liabilities 159.67
Total current financial liabilities 13,964.85
Other current liabilities 11,040.56
1 Other current liabilities 11,040.56
Total of other current liabilities 11,040.56
Provisions, current 277.96
Current tax liabilities (Net) 619.78
Deferred government grants, Current
Total current liabilities 25,903.15
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 29,369.86
Total equity and liabilites 1,75,428.51
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss 0.00 0.00
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 0.00 0.00



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 7,267.03
Adjustments for reconcile profit (loss)
Adjustments for finance costs 0.00
Adjustments for decrease (increase) in inventories (2,537.57)
Adjustments for decrease (increase) in trade receivables, current (5,236.66)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (3,068.50)
Adjustments for decrease (increase) in other non-current assets 358.80
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 0.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 1,535.39
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 0.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 548.19
Adjustments for dividend income 0.00
Adjustments for interest income 0.00
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow (1,445.30)
Other adjustments to reconcile profit (loss) 68.04
Other adjustments for non-cash items 51.18
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (9,726.43)
Net cash flows from (used in) operations (2,459.40)
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 1,088.92
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities (3,548.32)
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 0.00
Purchase of property, plant and equipment 6,700.72
Proceeds from sales of investment property 0.00
Purchase of investment property 3,837.42
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 1,454.33
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) investing activities (9,083.81)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 3,430.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 177.43
Repayments of borrowings 0.00
Payments of lease liabilities 0.00
Dividends paid 0.00
Interest paid 108.31
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (85.48)
Net cash flows from (used in) financing activities 3,413.64
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (9,218.49)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents (9,218.49)
Cash and cash equivalents cash flow statement at beginning of period 41,499.12
Cash and cash equivalents cash flow statement at end of period 32,280.63





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Unaudited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 RATTAN KAUR AND ASSOCIATES Yes 31-01-2027


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)

Amount in (Lakhs)

Mode of Fund Raising Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 30-08-2024
Amount Raised 25,561.25
Report filed for Quarter ended 30-09-2026
Monitoring Agency Applicable
Monitoring Agency Name, if applicable CARE RATINGS LIMITED
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation
Comments of the Audit Committee after review
Comments of the auditors, if any
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Expansion of Business of the Company or the Wholly Owned Subsidiaries NIL 15,000.00 0.00 11,354.16 0.00
2 Investment in existing or to be acquired Subsidiaries NIL 5,000.00 0.00 2,747.07 0.00
3 Working Capital for existing business NIL 3,960.00 0.00 3,960.00 0.00
4 General Corporate Purpose NIL 7,500.00 0.00 3,960.00 0.00


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (2)

Amount in (Lakhs)

Mode of Fund Raising Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 17-09-2026
Amount Raised 3,430.00
Report filed for Quarter ended 30-09-2026
Monitoring Agency Applicable
Monitoring Agency Name, if applicable CARE RATINGS LIMITED
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation
Comments of the Audit Committee after review
Comments of the auditors, if any
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Expansion of Existing Manufacturing Facility and Setting up of a new Warehouse NIL 4,140.00 0.00 631.48 0.00
2 Research & Development (‘R&D’) NIL 200.00 0.00 33.47 0.00
3 Technology Upgradation NIL 150.00 0.00 0.00 0.00
4 Investment in subsidiary NIL 500.00 0.00 485.30 0.00
5 To meet the Working Capital Requirements of the Company NIL 5,300.00 0.00 398.96 0.00
6 General Corporate Purpose NIL 3,430.00 0.00 10.80 0.00


Signatory Details

Name of signatory PARDEEP VERMA
Designation of person Company Secretary and Compliance Officer
Place Chandigarh
Date 29-10-2026




Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 IND-SWIFT LABORATORIES LIMITED ESSIX BIOSCIENCES LIMITED Promoter Investment 1,50,000.00 As approved by Board/Shareholders 0.00 2,885.06 2,885.06
2 IND-SWIFT LABORATORIES LIMITED ESSIX BIOSCIENCES LIMITED Promoter Purchase of goods or services 15,000.00 As approved by Board/Shareholders 1,707.83 3,299.73 1,429.65
3 IND-SWIFT LABORATORIES LIMITED MOHALI GREEN ENVIRONMENT PRIVATE LIMITED Other RP Advance 500.00 As approved by Board/Shareholders 0.00 22.00 22.00
4 IND-SWIFT LABORATORIES LIMITED MOHALI GREEN ENVIRONMENT PRIVATE LIMITED Other RP Investment 1,50,000.00 As approved by Board/Shareholders 0.00 3.00 3.00
5 IND-SWIFT LABORATORIES LIMITED IND-SWIFT LABORATORIES INC, USA Wholly Owned Subsidiary Sale of goods or services Being a wholly owned subsidiary, there is no requirement 771.27 96.03 369.45
6 IND-SWIFT LABORATORIES LIMITED IND-SWIFT LABORATORIES INC, USA Wholly Owned Subsidiary Investment Being a wholly owned subsidiary, there is no requirement 0.00 544.10 544.10
7 IND-SWIFT LABORATORIES LIMITED FORTUNE (INDIA) CONSTRUCTIONS LIMITED Wholly Owned Subsidiary Investment Being a wholly owned subsidiary, there is no requirement 0.00 7,248.40 7,248.40
8 IND-SWIFT LABORATORIES LIMITED NAVRATTAN MUNJAL Promoter Remuneration As approved by NRC/Board 221.28 72.91 72.78
9 IND-SWIFT LABORATORIES LIMITED HIMANSHU JAIN Promoter Remuneration As approved by NRC/Board 162.19 51.39 51.67
10 IND-SWIFT LABORATORIES LIMITED RISHAV MEHTA Promoter Remuneration As approved by NRC/Board 177.01 34.95 35.82
11 IND-SWIFT LABORATORIES LIMITED SAHIL MUNJAL Promoter Remuneration As approved by NRC/Board 177.01 56.56 53.61
12 IND-SWIFT LABORATORIES LIMITED GAGAN AGGARWAL CFO Remuneration As approved by NRC/Board 33.48 0.00 0.00
13 IND-SWIFT LABORATORIES LIMITED PARDEEP VERMA Company Secretary Remuneration As approved by NRC/Board 25.64 0.00 0.00
14 IND-SWIFT LABORATORIES LIMITED PARDEEP VERMA Company Secretary Any other transaction Loans & Advances As approved by NRC/Board 0.00 3.21 3.21
15 IND-SWIFT LABORATORIES LIMITED INDIS HEALTHCARE LLP Joint Venture Investment 1,000.00 Within the maximum limit as approved by the Board 0.00 250.00 250.00
16 IND-SWIFT LABORATORIES LIMITED INDIS HEALTHCARE LLP Joint Venture Sale of goods or services 5,000.00 Within the maximum limit as approved by the Board 101.86 89.37 92.90
17 IND-SWIFT LABORATORIES LIMITED MJM REMEDIES PRIVATE LIMITED Subsidiary Investment 50.00 Within the maximum limit as approved by the Board 0.00 23.25 23.25
18 IND-SWIFT LABORATORIES LIMITED ESSIX BIOSCIENCES LIMITED Promoter Sale of goods or services 15,000.00 As approved by Board/Shareholders 0.13 0.77 0.06
19 IND-SWIFT LABORATORIES LIMITED MJM REMEDIES PRIVATE LIMITED Subsidiary Sale of goods or services 5,000.00 as approved by audit committee 0.00 8.16 8.16
20 IND-SWIFT LABORATORIES LIMITED ELAN VITAL DRUG STORE LLC Other RP Sale of goods or services 5,000.00 as approved by audit committee 513.55 967.07 1,298.59
21 IND-SWIFT LABORATORIES LIMITED CHDMM TIBBI OMEHTA Other RP Sale of goods or services 5,000.00 as approved by audit committee 26.94 331.32 304.38
22 IND-SWIFT LABORATORIES LIMITED GOPAL MUNJAL Promoter Any other transaction Advance against salary as per HR's policy 0.00 345.79 345.79
23 IND-SWIFT LABORATORIES LIMITED S.R. MEHTA Promoter Any other transaction Advance against salary as per HR's policy 0.00 363.19 363.19
24 IND-SWIFT LABORATORIES LIMITED V.R. MEHTA Promoter Any other transaction Advance against salary as per HR's policy 0.00 356.18 356.18
25 IND-SWIFT LABORATORIES LIMITED MUNJAL JAIN ESTATES PVT LTD Other RP Loan 1,000.00 1000 26.60 466.18 447.78
26 IND-SWIFT LABORATORIES LIMITED ISLL MIDDLE EAST L.L.C -FZ Wholly Owned Subsidiary Investment Being a wholly owned subsidiary, there is no requirement 484.75 2,746.17 3,230.92
27 FORTUNE (INDIA) CONSTRUCTIONS LIMITED ESSIX BIOSCIENCES LIMITED Other RP Investment as approved by audit committee 0.00 1,556.93 1,556.93 Textual Information(1)
28 FORTUNE (INDIA) CONSTRUCTIONS LIMITED ESSIX BIOSCIENCES LIMITED Other RP Investment as approved by audit committee 0.00 380.55 380.55 Textual Information(2)
29 IND-SWIFT LABORATORIES LIMITED Gopal Munjal Promoter Remuneration 2,400.00 As approved by Shareholders 89.94 0.00 0.00
30 IND-SWIFT LABORATORIES LIMITED S.R. Mehta Promoter Remuneration 2,400.00 As approved by Shareholders 89.94 0.00 0.00
31 IND-SWIFT LABORATORIES LIMITED V.R. Mehta Promoter Remuneration 2,400.00 As approved by Shareholders 89.94 0.00 0.00
32 IND-SWIFT LABORATORIES LIMITED Capital Strikers LLP Joint ventures Investment 200.00 as approved by Board/Audit Committee 0.00 0.25 0.25
33 IND-SWIFT LABORATORIES LIMITED MJM REMEDIES PRIVATE LIMITED Subsidiary Advance 5,000.00 as approved by Board/Audit Committee 6.75 0.00 6.75
Total value of transaction during the reporting period 4,706.11



Text Block

Textual Information(1) The outstanding balance pertains to the period prior to Fortune (India) Constructions Limited becoming a subsidiary of the Company. Fortune (India) Constructions Limited became a subsidiary during FY 2021-22; accordingly, the balance relates to transactions existing before the acquisition.
Textual Information(2) The outstanding balance pertains to the period prior to Fortune (India) Constructions Limited becoming a subsidiary of the Company. Fortune (India) Constructions Limited became a subsidiary during FY 2021-22; accordingly, the balance relates to transactions existing before the acquisition.